Xtandi
FDA Approves Xtandi for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
The FDA approved enzalutamide (Xtandi, Astellas Pharma) for nonmetastatic castration-sensitive prostate cancer ...
NOVEMBER 18, 2023
Continuing Enzalutamide After Progression and Adding Docetaxel Improved PFS in mCRPC, Study Shows
Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended ...
MARCH 25, 2022
Xtandi Granted New Indication: Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved the use of enzalutamide (Xtandi, Pfizer/Astellas) for the treatment of patients with ...
DECEMBER 18, 2019
Xtandi Gets Green Light From FDA for Nonmetastatic CRPC
The FDA approved the use of enzalutamide (Xtandi, Astellas) for patients with nonmetastatic castration-resistant ...
JULY 18, 2018
Load more